synthetic peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-11-01. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Statistical, likelihood-based approaches: Statistical, likelihood-based iterative expectation-maximization algorithms such as the Shepp–Vardi algorithm are now the preferred method of reconstruction. These algorithms compute an estimate of the likely distribution of annihilation events that led to the measured data, based on statistical principles. The advantage is a better noise profile and resistance to the streak artifacts common with FBP, but the disadvantage is greater computer resource requirements. A further advantage of statistical image reconstruction techniques is that the physical effects that would need to be pre-corrected for when using an analytical reconstruction algorithm, such as scattered photons, random coincidences, attenuation and detector dead-time, can be incorporated into the likelihood model being used in the reconstruction, allowing for additional noise reduction. Iterative reconstruction has also been shown to result in improvements in the resolution of the reconstructed images, since more sophisticated models of the scanner physics can be incorporated into the likelihood model than those used by analytical reconstruction methods, allowing for improved quantification of the radioactivity distribution. Research has shown that Bayesian methods that involve a Poisson likelihood function and an appropriate prior probability (e.g., a smoothing prior leading to total variation regularization or a Laplacian distribution leading to
Lymphedema is the swelling caused by the accumulation of lymph, which may occur if the lymphatic system is damaged or has malformations. It usually affects limbs, though the face, neck, and abdomen may also be affected. In an extreme state, called elephantiasis, the edema progresses to the extent that the skin becomes thick with an appearance similar to the skin on elephant limbs. Causes are unknown in most cases, but sometimes there is a previous history of severe infection, usually caused by a parasitic disease, such as lymphatic filariasis. Lymphangiomatosis is a disease involving multiple cysts or lesions formed from lymphatic vessels. Lymphedema can also occur after surgical removal of lymph nodes in the armpit (causing the arm to swell due to poor lymphatic drainage) or groin (causing swelling of the leg). Conventional treatment is by manual lymphatic drainage and compression garments. Two drugs for the treatment of lymphedema are in clinical trials: Lymfactin and Ubenimex/Bestatin. There is no evidence to suggest that the effects of manual lymphatic drainage are permanent.
Limb-girdle muscular dystrophy; Inflammatory myopathy. Allelic to McArdle disease (GSD-V) is a disease that has a pathogenic autosomal dominant mutation in exon 16 of the PYGM gene c.1915G>C (p.Asp639His). Discovered in 2020, it affected 13 members of a family over four generations and has yet to be assigned a GSD number. Unlike McArdle disease (GSD-V), this disease does not have an overall deficiency of myophosphorylase, only a deficiency of functioning myophosphorylase-a with plenty of functioning myophosphorylase-b (similar to GSD-IXd). Myophosphorylase-b can be allosterically activated to break down glycogen (glycogenolysis) by high levels of AMP, and as the AMP-dependent activity was preserved, the individuals of this family had normal muscle glycogen concentrations as well as lacked exercise intolerance (which are prominent distinguishing features from McArdle disease). The only symptom was adult-onset (40+ years of age) fixed muscle weakness, initially of the proximal muscles of the legs, followed by proximal arms, then distal leg muscles. Muscle biopsy also showed accumulation of the intermediate filament desmin in the myofibres.
Sources: en.wikipedia.org
== Promotion == In March 2006, it was announced that "Come What May," would be released on July 18, 2006. However, the release date for the album was pushed back until August 22. Because of the delay, Stone Sour released a music video for the track "Reborn", which had footage of the band working on the album in the studio. The album's cover artwork was released online on May 20, 2006. Shortly after, it was confirmed by a representative from the band's record label, Roadrunner, that the release date had been brought forward, and the official release date would be August 1, 2006. On July 31, 2006, the day before its release the album was made available online for streaming in its entirety through AOL. On May 22, 2006, the first single from the album, "30/30-150", was made available online as a free MP3 download. A music video for the single was shot with director P.R. Brown in Los Angeles and received a premier on MTV's Headbangers Ball on June 3, 2006. Prior to the release of the second single from the album, "Through Glass", radio stations throughout the US showed high support for the song. A music video for the single was shot with director Tony Petrossian and was released online on June 9, 2006, through Yahoo!. The third single from the album, "Sillyworld", began receiving radio airplay in November 2006. A music video for the single was shot in January 2007 and was released online on March 8, 2007. The fourth single from the album, "Made of Scars", had a music video which was recorded live on April 7, 2007, and was posted online on June 5, 2007.
8 October – Tánaiste Micheál Martin said that the Department of Foreign Affairs had been in touch with the family of Kim Damti (22), an Irish-Israeli woman who was unaccounted for following the previous day's series of attacks launched by Hamas on Israel. On 11 October, Damti was confirmed dead. 10 October – Minister for Finance Michael McGrath and Minister for Public Expenditure, National Development Plan Delivery and Reform Paschal Donohoe announced Budget 2024, with three electricity credits for all households, a €12 increase to core social welfare payments and half-price travel for those aged under 25. 23 October – Yousef Palani was sentenced to two life sentences plus 20 years for the murder of two men and the stabbing of a third in Sligo, all of who he had sought out on a pretence of dating. 25 October – The Health Products Regulatory Authority (HPRA) said it had seized 254 units of falsified Semaglutide, a drug used for type 2 diabetes and as an unofficial aide to weight loss, during 2023. 27 October – Latest figures showed that homelessness in Ireland hit new records: 8,923 adults and 3,904 children accessed emergency accommodation in September 2023, bringing the total to 12,827 people.
==== Hemisphere effect ==== The northern and southern hemispheres have atmospheric circulation systems that are sufficiently independent of each other that there is a noticeable time lag in mixing between the two. The atmospheric 14C/12C ratio is lower in the southern hemisphere, with an apparent additional age of about 40 years for radiocarbon results from the south as compared to the north. This is because the greater surface area of ocean in the southern hemisphere means that there is more carbon exchanged between the ocean and the atmosphere than in the north. Since the surface ocean is depleted in 14C because of the marine effect, 14C is removed from the southern atmosphere more quickly than in the north. The effect is strengthened by strong upwelling around Antarctica.
Sources: en.wikipedia.org
=== 1950s === In 1953, the company became a public company via an initial public offering on the New York Stock Exchange. In 1954, the company acquired Davison Chemical Company and Dewey & Almy Chemical Company, entering the specialty chemicals and specialty materials industries and establishing the basis for the current product lines. In 1955, the company elected a chairman of the company who was not a member of the Grace family, which was a first in the 101-year history of company. The company appointed Charles E. Wilson, who was the former CEO of General Electric. His predecessor for his position was William Grace Holloway.
== History == RNAP was discovered independently by Sam Weiss, Audrey Stevens, and Jerard Hurwitz in 1960. By this time, one half of the 1959 Nobel Prize in Medicine had been awarded to Severo Ochoa for the discovery of what was believed to be RNAP, but instead turned out to be polynucleotide phosphorylase.
Chest trauma leading to aortic dissection can be divided into two groups based on cause: blunt chest trauma (commonly seen in car accidents) and iatrogenic. Iatrogenic causes include trauma during cardiac catheterization or due to an intra-aortic balloon pump. Aortic dissection may be a late sequela of heart surgery. About 18% of individuals who present with an acute aortic dissection have a history of open-heart surgery. Individuals who have undergone aortic valve replacement for aortic insufficiency are at particularly high risk because aortic regurgitation causes increased blood flow in the ascending aorta. This can cause dilatation and weakening of the walls of the ascending aorta. In December 2018, the U.S. Food and Drug Administration (FDA) issued a warning that fluoroquinolones may increase the risk of aortic aneurysm and aortic dissection, particularly in older adults and in patients with hypertension, Marfan syndrome, Ehlers-Danlos syndrome, atherosclerosis, peripheral vascular disease, or a history of aneurysms. Syphilis only potentially causes aortic dissection in its tertiary stage.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.